Skip to content

Insy therapeutics股票价格

Insy therapeutics股票价格

Insys Therapeutics Inc(INSY)股票行情_Insys Therapeutics Inc股票 ... 金投美股网提供Insys Therapeutics Inc(INSY)股票行情,Insys Therapeutics Inc股票价格,Insys Therapeutics Inc股票走势分析,Insys Therapeutics Inc股票最新消息等数据分析,包括公司基本资料、重大新闻及相关公告。 (insy)股票高管交易状况_美股_新浪财经_新浪网 (insy)股票高管交易状况,信息或数据由新浪财经美股频道提供 (INSY)股票高管交易状况_美股_新浪财经_新浪网 (INSY)股票高管交易状况,信息或数据由新浪财经美股频道提供 INSYS Therapeutics, Inc. (INSY) 价格; 2019-03-03 Bohlen (Elizabeth) Director Buy: 8083--2019-03-03 Meyer

[Ta1le_Main] [Table_Title] 医药生物 结合基因编辑 CRISPR 技术,2.0 版 CAR-T 照亮治癌之路 [Table_InvestRank] 评级: 增持 前次: 增持 分析师 孙建 S0740515080002 021-20315160 2016 年 01 月 28 日 [Table_Profit] 基本状况 上市公司数 208 行业总市值(百万元) 2709902.584 94186 行业流通市值(百万元) 2709902.584 94186

INSYS THERAPEUTICS, INC. (INSY) stock price, charts, trades & the US's most popular discussion forums. Free forex prices, toplists, indices and lots more. INSY is flying high after posting 9% gains on the strength of Insys Therapeutics' now-FDA-approved drug, Syndros. Load More InfraCap REIT Preferred ETF declares $0.12 dividend (NYSEARCA:PFFR) 简介: Insys Therapeutics Inc是一家生物技术公司,开发和商业化创新药物和新型药物输送系统。 该公司维持大麻素的配方和制造以及舌下喷雾药物输送技术,以开发一系列差异化,全资拥有的产品候选人。 Insys继续专门针对肿瘤医疗保健提供者和实践。

Real time Insys Therapeutics (INSY) stock price quote, stock graph, news & analysis.

Insys Therapeutics closed the most recent trading day at $4.81, moving +1.69% from the previous trading session. This change outpaced the S&P 500's 1.09% gain on the day. INSY Description — Insys Therapeutics Inc. Insys Therapeutics is a commercial-stage pharmaceutical company that develops and commercializes supportive care products. Co. has two marketed product: SUBSYS®, a proprietary sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS®, a proprietary Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. The company was founded in 2002 and is based in Chandler, Arizona. View our full INSY ticker page with ratings, news, and more. Insys Therapeutics AKTIE (ISIN: US45824V2097) | Aktienkurs der Insys Therapeutics Aktie, Finanznachrichten und Charts, Analysen, Kennzahlen, Buzz & Sentiment Trends

值 物价 股票 图表 历史上 收益 股息收益率 - INSY Insys Therapeutics 股票价格 - 5/27/2020.

美股相关新闻. finviz | 2019年06月20日 19:36 Opinion: Medical Marijuana Is a Terrible Investment; finviz | 2019年06月13日 00:27 Insys Therapeutics Bankruptcy: INSY Stock Soars on Latest News; finviz | 2019年06月12日 21:39 Zynerba Up on Second Patent for Cannabidiol Candidate in 2019; finviz | 2019年06月12日 21:27 Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & Insys Therapeutics is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products. We have two marketed products, Subsys and Dronabinol SG Capsule, which leverage our sublingual spray drug delivery technology and dronabinol formulation and manufacturing capabilities, respectively. InSys Therapeutics, Inc. Author: Jordan McLean Created Date: 6/8/2017 3:14:46 PM Insys Therapeutics, Inc. develops cancer support drugs. The Company support care candidates include a fast-acting sublingual spray for cancer pain and a dronabinol product used to treat Insys Therapeutics has 226 employees across 3 locations and $82.08 M in annual revenue in FY 2018. See insights on Insys Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. An ex-stripper who became a regional sales director at Insys Therapeutics Inc gave a doctor a lap dance at a Chicago club as the drugmaker pushed the doctor to prescribe its addictive fentanyl Docket for IN RE INSYS THERAPEUTICS, INC. SECURITIES LITIGATION, 1:17-cv-01954 — Brought to you by the RECAP Initiative and Free Law Project, a non-profit dedicated to creating high quality open legal information.

INSY is flying high after posting 9% gains on the strength of Insys Therapeutics' now-FDA-approved drug, Syndros. Load More InfraCap REIT Preferred ETF declares $0.12 dividend (NYSEARCA:PFFR)

Insys Therapeutics. May 01, 2020. Go or no go? Oncology dominates upcoming decisions . Astrazeneca's Lynparza is due US approval decisions in prostate and ovarian cancers, while Bristol's Opdivo's fate will be determined in lung cancer. July 05, 2019. Insys Therapeutics Inc. et al., case number 2:16-cv-00302, in the U.S. District Court for the District of Arizona. --Editing by Haylee Pearl. For a reprint of this article, please contact reprints

Apex Business WordPress Theme | Designed by Crafthemes